Clinical Trials Logo

Schizophrenia clinical trials

View clinical trials related to Schizophrenia.

Filter by:

NCT ID: NCT05870384 Recruiting - Family Caregivers Clinical Trials

Application of Group Interpersonal Psychotherapy (IPT-G) to Family Members Caring for Patients With Schizophrenia

IPT-G
Start date: July 2023
Phase: N/A
Study type: Interventional

The goal of this re-measured quasi-experimental study is to evaluate the effect of Group Interpersonal Psychotherapy (IPT-G) intervention given to caregiver family members of people with schizophrenia on caregiver burden, perception of social support and stigma, adherence to treatment in people with schizophrenia they care for, and emotional expression in both caregivers and people with schizophrenia they care for. The main hypotheses it aims to test are: 1. IPT-G intervention will reduce the caregiver burden of caregivers of individuals with schizophrenia. 2. IPT-G intervention will increase the perceived social support levels of caregivers of individuals with schizophrenia. 3. IPT-G intervention will reduce the level of stigma of caregivers of individuals with schizophrenia. 4. IPT-G intervention will reduce the level of emotional expression of caregivers of individuals with schizophrenia. 5. IPT-G intervention applied to caregivers will increase the level of adherence to treatment of individuals with schizophrenia they care for. 6. IPT-G intervention applied to caregivers will reduce the emotional expression levels of individuals with schizophrenia they care for.

NCT ID: NCT05859698 Recruiting - Schizophrenia Clinical Trials

Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia

Start date: May 25, 2023
Phase: Phase 4
Study type: Interventional

This study will evaluate the effectiveness of valbenazine on patient- and clinician-reported outcomes assessing health-related quality of life, functioning, and treatment effect in participants with tardive dyskinesia (TD) who are receiving valbenazine for up to 24 weeks.

NCT ID: NCT05858255 Recruiting - Clinical trials for Cognitive Impairment

Hjernegym - Effects of Exergaming in Psychosis: a Clinical Intervention Study

Start date: March 29, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical intervention study is to investigate the effects of exergaming on cognition and other clinical symptoms in outpatient individuals with schizophrenia. The main questions it aims to answer are: Will an exergaming intervention contribute to improved cognition and reduced clinical symptoms, as well as enhanced physical health/self-efficacy/quality of life, in individuals with schizophrenia? Will the gaming component strengthen motivation for a physically more intensive component, so that attendance will be at least as high as in comparable exercise studies despite the current study being implemented in a resource-limited, regular clinical outpatient setting? Participants will be asked to engage in two 45 minutes exergaming sessions with a designated personal trainer for 12 weeks. Results pre- and post intervention will be compared, and comparisons will also be made with a former randomized controlled trial conducted at the same site, in which the currently combined activities were investigated separately (high-intensity interval training and low-intensity video gaming), both yielding positive but different effects.

NCT ID: NCT05850923 Recruiting - Clinical trials for Auditory Hallucination

The Efficacy of Speech Competition Training on Auditory Hallucination in Schizophrenia

Start date: November 15, 2022
Phase: N/A
Study type: Interventional

One hundred schizophrenia patients with auditory hallucinations will be recruited and randomized into group A and group B. Participants of group A will firstly receive a speech competition training for 2 weeks, and those in group B will firstly receive music intervention as placebo treatment. Specifically, speech competition training include voice competition training twice a day in adjunction with drug treatment, and the patients will be required to perform voice-related tasks according to the instruction. The reaction time, accuracy rate and the number of auditory hallucinations during the task will be recorded. On the other hand, the placebo treatment includes soothing music twice a day for a fixed period of time while patients receiving drug treatment. After 2 weeks, the interventions for group A and group B will be switch. Clinical symptoms will be evaluated using the auditory hallucinations rating scale, positive and negative syndrome scale, belief about voices questionnaire-revised at baseline, 2-week follow up and 4-week follow up. All the data will be analyzed with the Statistical Product and Service Solutions(SPSS) software.

NCT ID: NCT05838625 Recruiting - Schizophrenia Clinical Trials

Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia

CONVOKE
Start date: March 31, 2023
Phase: Phase 3
Study type: Interventional

This study evaluates the efficacy of two prescription digital therapeutics (PDT) in addition to standard of care (SOC) therapy for the treatment of experiential negative symptoms of schizophrenia in late adolescents and adults.

NCT ID: NCT05838573 Recruiting - Schizophrenia Clinical Trials

Metformin Treatment on Cognitive Impairment of Schizophrenia

Start date: May 8, 2023
Phase: Phase 3
Study type: Interventional

In this study, the investigators will investigate the effect and the underlying mechanism of metformin treatment on cognitive impairment in individuals with schizophrenia. The study will recruit 120 individuals with schizophrenia at 4 sites, who will be randomized to metformin or placebo group for 24-week treatment. Clinical assessments will be done at screen/baseline, 12th week and 24th week. Participants who don't meet any of the diagnostic criteria for metabolic syndrome will only accept baseline evaluations. The specific aims are to compare healthy volunteers versus schizophrenic participants on:1) cognition; 2) MRI features, and to compare metformin group versus placebo group of 24-week treatment cohort on: 1) cognition; 2) clinical core symptoms; 3) MRI features. Biological samples also will be collected and stored to explore related mechanisms.

NCT ID: NCT05838560 Recruiting - Schizophrenia Clinical Trials

Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders

Start date: July 1, 2023
Phase: Phase 2
Study type: Interventional

This pilot open-label study examines the effects of a combination of dasatinib plus quercetin - two drugs that have known senolytics properties - on physiological aging in older individuals with depression or schizophrenia.

NCT ID: NCT05837598 Recruiting - Breast Cancer Clinical Trials

Adapting the Tumor Board Model for Mental Illness and Cancer

Start date: May 31, 2023
Phase: N/A
Study type: Interventional

This study examines the feasibility and acceptability of a virtual tumor board for cancer and mental illness for patients with serious mental illness and a new cancer diagnosis. The study also examines the impact on patient care, psychiatric symptoms, and clinician self-efficacy in managing this population.

NCT ID: NCT05833009 Recruiting - Schizophrenia Clinical Trials

Acupuncture Treatment for Schizophrenia-related Central Obesity

Start date: October 1, 2022
Phase: N/A
Study type: Interventional

This clinical trial aims to test the effect of acupuncture in patients with schizophrenia-related central obesity. The main question it aims to answer is: • The effect, safety, and maintenance of acupuncture on schizophrenia-related central obesity. Participants will receive acupuncture treatment on purpose acupoints, acupuncture on acupoint peripheries, or fake acupuncture treatment on purpose acupoints for 20 weeks. And they need three follow-up visits during the treatment period and two follow-up visits after treatment. Researchers will compare the waist circumstance of these three groups to see if the purpose acupoints are valid for schizophrenia-related central obesity.

NCT ID: NCT05830903 Recruiting - Schizophrenia Clinical Trials

Develop a Novel Occupational Training Program for Schizophrenia Patients Based on Virtual Reality Techniques

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

Establish a novel vocational training program and test its validity in a pilot study.